current
circul
subtyp
influenza
viru
caus
transient
febril
upper
respiratori
ill
adult
children
season
influenza
infant
elderli
immunodefici
chronic
ill
person
may
develop
lifethreaten
primari
viral
pneumonia
complic
bacteri
pneumonia
contrast
avian
influenza
virus
viru
recent
emerg
southeast
asia
caus
sever
diseas
transfer
domest
poultri
previous
healthi
peopl
avian
influenza
patient
present
fever
cough
short
breath
progress
rapidli
adult
respiratori
distress
syndrom
season
influenza
viral
replic
remain
confin
respiratori
tract
limit
studi
indic
infect
character
system
viral
dissemin
high
cytokin
level
multiorgan
failur
gastrointestin
infect
enceph
also
occur
licens
antiinfluenza
drug
ion
channel
blocker
amantadin
rimantadin
neuraminidas
inhibitor
oseltamivir
zanamivir
benefici
uncompl
season
influenza
appropri
dose
regimen
sever
season
viral
infect
defin
treatment
option
may
limit
rapid
emerg
drugresist
virus
ribavirin
also
use
limit
extent
treat
influenza
articl
review
licens
drug
treatment
develop
includ
highdos
oseltamivir
parenter
administ
neuraminidas
inhibitor
peramivir
zanamivir
dimer
form
zanamivir
rna
polymeras
inhibitor
ribavirin
prodrug
viramidin
polyval
monoclon
antibodi
combin
therapi
publish
elsevi
bv
influenza
virus
multipartit
negativesens
singlestrand
rna
genom
lipid
envelop
divid
three
genera
b
c
within
famili
orthomyxovirida
base
antigen
properti
viral
nucleoprotein
influenza
b
c
virus
princip
infect
human
usual
caus
mild
ill
children
undergo
gradual
antigen
variat
wright
webster
contrast
influenza
virus
maintain
vast
natur
reservoir
wild
waterfowl
shorebird
emerg
caus
diseas
domest
poultri
hors
pig
human
abil
infect
human
respiratori
tract
period
emerg
antigen
novel
agent
genom
reassort
enabl
influenza
virus
caus
worldwid
epidem
high
morbid
mortal
pandem
influenza
individu
isol
influenza
viru
classifi
subtyp
base
antigen
ident
two
glycoprotein
embed
virion
lipid
envelop
hemagglutinin
ha
neuraminidas
na
fig
studi
avian
virus
identifi
antigen
distinct
variant
ha
na
lead
exist
larg
number
viral
subtyp
differ
hana
pair
protect
immun
result
previou
infect
vaccin
base
princip
neutral
antibodi
ha
lesser
extent
antibodi
na
hayden
pales
emerg
new
pandem
subtyp
influenza
viru
occur
two
pathway
first
avian
viru
infect
caus
diseas
human
avian
influenza
evolv
cours
ill
becom
transmiss
person
person
second
made
possibl
multipartit
genom
permit
circul
season
agent
acquir
new
ha
na
gene
reassort
antigen
shift
cell
coinfect
season
viru
either
avian
viru
one
adapt
mammalian
host
pig
novel
virus
emerg
sever
time
centuri
avian
viru
acquir
fig
influenza
viru
replic
cycl
virion
core
contain
eight
rna
genom
segment
encapsid
nucleoprotein
rnp
embed
togeth
associ
polymeras
p
molecul
matrix
protein
bind
sialic
acidgalactos
link
cellsurfac
glycoprotein
glycolipid
virion
taken
endocyt
vesicl
acidif
trigger
conform
chang
bring
viral
endosom
membran
togeth
acidif
also
produc
flow
proton
ion
channel
interior
virion
caus
rnp
dissoci
matrix
releas
cytoplasm
transport
nucleu
viral
polymeras
complex
perform
transcript
genom
replic
result
mrna
move
cytoplasm
translat
produc
new
rnp
protein
compon
transport
back
nucleu
associ
nascent
genom
segment
exit
new
rnp
nucleu
aid
viral
nuclear
export
protein
nep
meanwhil
nascent
ha
na
molecul
pass
golgi
apparatu
undergo
glycosyl
move
cell
membran
ha
also
cleav
form
two
chain
link
disulfid
bond
virion
assembl
occur
rnp
protein
associ
cytoplasm
tail
ha
na
success
releas
new
viru
particl
requir
na
cleav
sialic
acid
galactos
cell
surfac
adjac
virion
prevent
ha
bind
capac
effici
respiratori
transmiss
result
catastroph
pandem
viru
continu
circul
progress
accumul
mutat
gene
permit
antigen
drift
variant
return
reinfect
popul
caus
recurr
outbreak
ill
season
influenza
new
reassort
viru
appear
two
surfac
glycoprotein
replac
avian
second
reassort
event
produc
influenza
viru
soon
ceas
circul
new
viru
emerg
spread
around
world
influenza
morbid
mortal
increas
markedli
declin
human
popul
acquir
degre
immun
agent
underw
progress
antigen
drift
wright
webster
season
variant
viru
reappear
appar
accident
laboratori
releas
continu
circul
along
viru
human
pig
influenza
viru
novel
ha
enter
human
popul
sinc
emerg
new
pandem
strain
like
viru
might
obtain
ha
agent
avianswin
reassort
detect
usa
et
al
sever
pure
avian
strain
infect
human
past
decad
see
present
concern
scenario
would
pandem
spread
highli
virul
avian
viru
first
appear
hong
kong
caus
lethal
primari
viral
pneumonia
confirm
human
infect
chan
et
al
yuen
et
al
although
case
ceas
local
poultri
destroy
viru
continu
spread
reassort
among
wild
bird
sinc
reemerg
caus
poultri
outbreak
sporad
case
sever
human
ill
sever
southeast
asian
countri
beigel
et
al
li
et
al
carri
migratori
bird
transport
domest
poultri
indonesia
across
asia
africa
europ
decemb
total
confirm
human
case
report
countri
death
shinya
et
al
fortun
instanc
persontoperson
transmiss
document
vaccin
princip
defens
influenza
take
time
produc
antigen
appropri
immunogen
product
deliv
entir
popul
antivir
drug
princip
countermeasur
reduc
impact
new
pandem
monto
moscona
current
armamentarium
licens
antiinfluenza
medic
consist
four
drug
two
adamantan
amantadin
rimantadin
fig
two
na
inhibitor
oral
drug
oseltamivir
tamiflu
inhal
medic
zanamivir
relenza
fig
de
clercq
licensur
obtain
base
studi
healthi
adult
uncompl
season
influenza
littl
known
drug
use
treat
sever
diseas
particular
anecdot
inform
avail
treatment
fulmin
viru
infect
oseltamivir
therapi
sever
influenza
made
even
challeng
rapid
emerg
drugresist
virus
especi
treatment
adamantan
lack
approv
parenter
medic
administ
patient
incap
swallow
inhal
drug
licens
drug
antiinfluenza
activ
ribavirin
virazol
use
limit
extent
treat
sever
infect
see
fig
influenza
virion
two
major
surfac
glycoprotein
ha
bind
sialic
acid
coval
link
termin
galactos
oligosaccharid
glycoprotein
glycolipid
na
cleav
sialic
acid
galactos
fig
presenc
two
compet
activ
virion
surfac
appear
come
sialic
acid
coupl
galactos
present
respiratori
epitheli
cell
varieti
molecul
respiratori
mucu
even
oligosaccharid
compon
ha
na
therefor
need
minim
bind
ha
decoy
receptor
enabl
virion
reach
target
cell
depart
end
replic
cycl
na
genet
delet
influenza
viru
initi
infect
drastic
inhibit
nascent
virion
clump
togeth
unabl
spread
cell
monolay
matrosovich
et
al
wagner
et
al
ha
na
must
work
tandem
achiev
effici
infect
reassort
virus
new
combin
gene
may
replic
effici
influenza
viru
succe
cross
reservoir
host
anoth
speci
bind
specif
virion
ha
appear
play
role
determin
outcom
infect
ha
current
circul
virus
bind
preferenti
sialic
acid
coupl
linkag
galactos
present
cellsurfac
glycoprotein
throughout
human
respiratori
tract
help
explain
season
influenza
occasion
develop
primari
viral
pneumonia
ibricev
et
al
nichol
et
al
contrast
avian
virus
make
use
link
sialic
acid
occurr
viral
pneumonia
patient
hong
kong
outbreak
thought
absent
human
respiratori
epithelium
recent
studi
shown
link
sialic
acid
predomin
nasal
caviti
bronchi
link
sialic
acid
present
bronchiolar
line
cell
type
ii
pneumocyt
alveolar
macrophag
provid
possibl
explan
predomin
lower
respiratori
tract
symptom
patient
rapid
develop
ard
ibricev
et
al
shinya
et
al
van
riel
et
al
although
natur
distribut
sialic
acidgalactos
linkag
respiratori
tract
help
explain
aspect
sever
season
avian
influenza
clear
sole
determin
cours
infect
thu
shown
virus
abl
replic
explant
human
upper
respiratori
tract
tissu
season
virus
caus
fatal
infect
knockout
mice
lack
detect
link
sialic
acid
infect
cell
sialic
acid
enzymat
remov
glaser
et
al
nichol
et
al
stray
et
al
pandem
virus
continu
circul
undergo
slow
antigen
drift
return
infect
popul
caus
gener
mild
ill
healthi
children
adult
character
fever
malais
nasal
congest
sneez
upper
respiratori
symptom
resolv
within
day
without
specif
therapi
young
children
experienc
first
bout
influenza
tend
shed
viru
longer
person
reinfect
viral
subtyp
gener
suffer
ill
effect
sato
et
al
howev
season
virus
also
caus
sever
diseas
young
infant
elderli
peopl
immunodefici
cardiopulmonari
diseas
chronic
ill
unit
state
influenza
viru
infect
respons
nearli
death
everi
year
sever
season
influenza
occur
viral
infect
spread
upper
lower
respiratori
tract
produc
primari
influenza
pneumonia
character
respiratori
distress
hypoxemia
hypotens
bilater
interstiti
infiltr
wright
webster
bacteri
pneumonia
also
develop
either
simultan
follow
influenza
viru
infect
limit
studi
shown
patient
uncompl
influenza
stop
shed
viru
nasopharyng
secret
third
day
ill
viru
often
detect
day
longer
symptom
onset
sever
ill
hospit
patient
ison
et
al
leekha
et
al
mcgeer
et
al
nicholson
et
al
treanor
et
al
prolong
viral
shed
despit
antivir
therapi
common
immunocompromis
person
especi
transplant
recipi
ison
et
al
drugresist
virus
often
emerg
set
avian
influenza
subtyp
caus
mild
infect
ill
human
bear
webster
viru
caus
outbreak
among
poultri
worker
netherland
peopl
develop
conjunct
influenzalik
ill
one
die
primari
viral
pneumonia
koopman
et
al
viru
caus
ill
indistinguish
season
influenza
number
children
hong
kong
peiri
et
al
butt
et
al
viru
caus
conjunct
mild
respiratori
tract
ill
two
confirm
case
canada
tweed
et
al
viru
emerg
southeast
asia
much
virul
avian
influenza
virus
unusu
broad
host
rang
caus
lethal
diseas
mani
speci
wild
domest
bird
small
larg
felin
rodent
primat
viru
recov
hong
kong
pathogen
mice
subtyp
virus
dybe
et
al
isol
recov
sinc
even
virul
mice
ferret
capabl
without
prior
adapt
caus
sever
pulmonari
diseas
spread
outsid
respiratori
tract
infect
multipl
organ
includ
brain
main
et
al
although
mild
case
identifi
patient
viru
infect
southeast
asia
turkey
develop
sever
pulmonari
diseas
patient
typic
present
fever
cough
difficulti
breath
primari
viral
pneumonia
develop
quickli
pulmonari
infiltr
chest
xray
beigel
et
al
buchi
et
al
de
jong
et
al
oner
et
al
et
al
yuen
et
al
ventilatori
support
usual
requir
within
h
hospit
admiss
limit
patient
studi
indic
contrast
season
influenza
sign
lower
respiratori
tract
involv
promin
upper
respiratori
tract
symptom
viral
titer
higher
pharyng
nasal
secret
de
jong
et
al
ill
progress
rapidli
acut
respiratori
distress
syndrom
ard
multiorgan
failur
pattern
reminisc
sever
acut
respiratori
syndrom
sar
ng
et
al
diarrhea
also
common
patient
present
sever
diarrhea
andor
neurolog
chang
progress
rapidli
lethal
enceph
pulmonari
diseas
either
develop
late
absent
apisarnthanarak
et
al
de
jong
et
al
clinic
laboratori
patholog
find
includ
leukopenia
mark
lymphopenia
low
tcell
count
thrombocytopenia
hemophagocytosi
hepat
central
lobular
necrosi
acut
renal
tubular
necrosi
note
rapid
develop
primari
viral
pneumonia
infect
may
reflect
abil
viral
ha
bind
link
sialic
acid
human
bronchioloalveolar
cell
includ
type
ii
pneumocyt
latter
cell
give
rise
new
squamou
type
pneumocyt
follow
type
lung
injuri
loss
viral
infect
could
lead
ard
sever
ill
may
also
reflect
intens
widespread
viral
replic
occur
season
influenza
number
factor
may
also
contribut
heighten
virul
viru
includ
greater
suppress
host
type
interferon
respons
protein
garciasastr
effici
function
rna
polymeras
salomon
et
al
alter
activ
protein
enhanc
viral
replic
reflect
high
titer
viru
nasopharyng
pharyng
secret
presenc
viral
rna
spleen
small
larg
intestin
cerebrospin
fluid
blood
fatal
case
detect
pcr
buchi
et
al
de
jong
et
al
uiprasertkul
et
al
seri
patient
studi
de
jong
et
al
extens
viral
replic
accompani
high
level
cytokin
chemokin
plasma
titer
proport
pharyng
viral
load
highest
fatal
case
appar
abil
recent
isol
induc
intens
inflammatori
respons
season
influenza
virus
mirror
find
laboratori
primari
human
macrophag
infect
hong
kong
viru
produc
significantli
cell
infect
season
virus
respons
profil
similar
induc
lipopolysaccharid
cheung
et
al
seo
et
al
recent
isol
also
induc
much
stronger
secret
rant
viru
primari
human
bronchial
epitheli
cell
type
ii
pneumocyt
chan
et
al
howev
studi
knockout
mice
given
contradictori
result
either
show
absenc
respons
reduc
mortal
anim
lack
function
receptor
suffer
milder
ill
szretter
et
al
case
evid
intens
inflammatori
respons
seen
case
regard
caus
ill
glucocorticoid
treatment
improv
outcom
infect
mice
alter
cours
fatal
ill
human
arabi
et
al
carter
salomon
et
al
although
suggest
intens
inflammatori
respons
seen
influenza
constitut
form
immun
dysregul
cytokin
storm
osterholm
may
simpli
consequ
sever
extens
viral
infect
treatment
antiinfluenza
viru
antibodi
could
potenti
benefit
sever
influenza
prevent
bind
virion
target
cell
fig
step
mark
infect
cell
destruct
complement
cell
immunoglobulin
product
clinic
use
extens
effort
assess
therapi
took
place
pandem
sever
ill
patient
sometim
treat
whole
blood
plasma
serum
convalesc
survivor
publish
report
review
luke
et
al
overal
case
fatal
rate
among
patient
receiv
convalesc
blood
product
untreat
patient
die
luke
et
al
distinct
improv
patient
condit
often
note
follow
therapi
along
line
b
h
recent
report
prompt
recoveri
sever
ill
patient
treat
plasma
convalesc
survivor
definit
evid
antibodi
efficaci
obtain
laboratori
anim
ramiss
et
al
demonstr
normal
human
immunoglobulin
ivig
contain
suffici
antiinfluenza
antibodi
protect
mice
lethal
pneumonia
inocul
intranas
h
infect
viru
f
ab
fragment
equal
activ
indic
protect
base
neutral
rather
fcreceptorbear
cell
complement
recent
lu
et
al
show
singl
inject
purifi
f
ab
fragment
deriv
immunoglobulin
hyperimmun
hors
protect
mice
lethal
viru
challeng
murin
monoclon
antibodi
mab
target
conserv
site
ha
virus
protect
mice
agent
okuno
et
al
mab
given
either
intact
fab
fragment
prevent
lethal
infect
scid
mice
mozdzanowska
et
al
palladino
et
al
human
mab
also
prevent
death
given
mice
day
otherwis
lethal
viru
challeng
hanson
et
al
similarli
fulli
human
mab
develop
use
immort
b
cell
vietnames
survivor
protect
mice
administ
h
viru
challeng
simmon
et
al
although
ha
import
target
antibodi
respons
pool
serum
mice
immun
na
season
viru
crossprotect
mice
viru
suggest
person
previous
infect
viru
partial
resist
gillimross
subbarao
sandbult
et
al
although
artifici
gener
antibodi
appear
therapeut
potenti
pool
human
immunoglobulin
convalesc
patient
vaccine
may
prove
efficaci
set
sever
ill
may
readili
approv
human
use
effort
therefor
initi
develop
polyclon
immunoglobulin
avian
influenza
intraven
administr
plasmapheresi
vaccin
recipi
wwwclinicaltrialsgov
mechan
develop
block
bind
virion
ha
sialic
acid
target
cell
includ
topic
deliveri
recombin
sialidas
remov
sialic
acid
malakhov
et
al
treatment
natur
occur
cyanobacteri
lectin
cyanovirin
bind
highmannos
oligosaccharid
virion
ha
okeef
et
al
adamantan
amantadin
rimantadin
exert
antivir
activ
block
ion
channel
prevent
virion
uncoat
releas
genom
segment
cytoplasm
fig
step
histor
use
almost
exclus
prevent
infect
reduc
durat
uncompl
season
influenza
benefit
treat
sever
diseas
defin
adamantan
inexpens
highli
stabl
storag
treatment
frequent
complic
gastrointestin
central
nervou
system
sideeffect
use
also
significantli
restrict
rapid
emerg
drugresist
virus
retain
full
virul
transmiss
hayden
although
commun
isol
influenza
viru
still
sensit
adamantan
resist
virus
increas
rapidli
isol
asia
unit
state
drugresist
bright
et
al
bright
et
al
chang
attribut
avail
overthecount
amantadin
hayden
licensur
memantin
amantadin
deriv
use
treat
alzheim
diseas
shah
use
amantadin
prevent
viral
infect
poultri
farm
china
cyranoski
resist
also
widespread
recent
emerg
asian
virus
poultryderiv
isol
china
none
thailand
sensit
drug
buranathai
et
al
cheung
et
al
et
al
therefor
recommend
amantadin
rimantadin
use
prevent
treat
infect
unless
infect
viru
known
like
sensit
schunemann
et
al
ribavirin
virazol
guanosin
analogu
licens
treatment
hepat
c
combin
aerosol
therapi
respiratori
syncyti
viru
infect
infant
fig
compound
act
indirectli
lower
intracellular
gtp
level
inhibit
inosin
monophosph
dehydrogenas
directli
interf
transcript
genom
replic
fig
step
multipl
mechan
action
ribavirin
abl
inhibit
broad
rang
rna
dna
virus
resist
virus
rare
observ
see
leyssen
et
al
ribavirin
less
activ
influenza
virus
adamantan
na
inhibitor
earli
evalu
oncedaili
oral
dose
g
ribavirin
begun
onset
symptom
effect
cours
ill
benefit
observ
dosag
quadrupl
smith
et
al
stein
et
al
aerosol
ribavirin
also
reduc
durat
fever
young
children
influenza
sometim
caus
bronchospasm
knight
gilbert
rodriguez
et
al
contrast
licens
antiinfluenza
drug
ribavirin
avail
intraven
form
deliv
manner
ribavirin
elimin
viru
two
patient
produc
improv
third
sever
influenza
parainfluenza
viru
infect
hayden
et
al
howev
drug
clinic
util
may
limit
risk
hemolyt
anemia
teratogen
properti
proscrib
use
pregnant
women
viramidin
prodrug
ribavirin
similar
activ
season
influenza
virus
less
toxic
fig
sidwel
et
al
interestingli
efficaci
lethal
viru
demonstr
mice
drug
administ
drink
water
perhap
viramidin
less
inhibitori
effect
cellular
dna
synthesi
ribavirin
produc
significantli
lower
incid
hemolyt
anemia
gish
drug
phase
trial
treatment
hepat
c
pyrazin
deriv
broadspectrum
inhibitor
rna
virus
includ
influenza
b
c
phase
test
fig
furuta
et
al
furuta
et
al
gowen
et
al
enter
cell
compound
initi
convert
monophosph
phosphoribosyl
transferas
triphosph
cellular
kinas
form
appear
inhibit
rnadepend
rna
polymeras
furuta
et
al
contrast
ribavirin
interfer
cellular
dna
rna
synthesi
littl
effect
imp
dehydrogenas
highli
activ
vitro
panel
season
influenza
virus
includ
amantadineand
oseltamivirresist
agent
high
dose
caus
cytotox
repeat
viru
passag
presenc
drug
result
resist
though
somewhat
less
activ
oseltamivir
influenza
virus
vitro
protect
vivo
lethal
model
viru
infect
mice
mgkgday
given
oral
begin
h
infect
prevent
death
reduc
lung
viral
titer
limit
detect
treatment
begun
h
gave
surviv
furuta
et
al
takahashi
et
al
mous
model
lethal
infect
oncedaili
treatment
prevent
death
even
initi
h
postinfect
anim
alreadi
ill
singl
larg
dose
nontox
highli
protect
consist
long
intracellular
halflif
antisens
dna
oligom
short
interf
rna
sirna
molecul
target
sequenc
influenza
viru
mrna
shown
efficaci
murin
avian
model
sever
influenza
ge
et
al
ge
et
al
tompkin
et
al
wu
et
al
h
zhou
et
al
provid
method
develop
deliv
effici
infect
cell
abil
block
translat
viral
mrna
fig
step
would
potenti
give
sequencebas
therapi
valuabl
role
treatment
human
diseas
approach
discuss
accompani
articl
spurger
et
al
issu
na
activ
requir
nascent
influenza
virion
exit
infect
cell
prevent
clump
analogu
sialic
acid
block
enzym
effect
antivir
drug
fig
step
fig
amino
acid
make
activ
site
highli
conserv
across
nine
known
na
subtyp
structur
na
potenti
approach
design
new
drug
discuss
detail
russel
et
al
multipl
control
trial
healthi
adult
cours
twicedaili
dose
mg
oseltamivir
shorten
cours
laboratoryconfirm
season
influenza
modest
extent
reduc
nasal
viral
titer
lower
incid
lower
respiratori
tract
complic
requir
antibiot
treatment
kaiser
et
al
nicholson
et
al
treanor
et
al
cooper
et
al
jefferson
et
al
treatment
effect
earlier
begun
diseas
cours
recent
studi
found
regimen
significantli
reduc
mortal
elderli
chronic
ill
patient
hospit
laboratoryconfirm
influenza
even
treatment
begun
h
symptom
onset
mcgeer
et
al
studi
laboratori
anim
indic
regimen
oseltamivir
develop
treat
uncompl
season
influenza
inadequ
infect
although
dose
mgkgday
day
suffici
prevent
death
mice
infect
hong
kong
viru
mgkgday
day
need
viru
viet
nam
govorkova
et
al
yen
et
al
ferret
infect
isol
mgkgday
start
h
inocul
prevent
death
mgkg
requir
therapi
delay
h
postchalleng
recent
guidelin
recommend
standard
regimen
oseltamivir
use
treat
patient
confirm
strongli
suspect
infect
schunemann
et
al
world
health
organ
howev
report
also
note
sever
ill
patient
might
benefit
higher
dose
mgday
andor
cours
therapi
prospect
studi
would
requir
establish
benefit
multicent
studi
initi
asia
us
june
compar
standard
vs
highdos
regimen
oseltamivir
mgday
vs
mgday
adult
normal
renal
function
day
day
therapi
sever
season
avian
influenza
clinicaltrialsgov
identifi
resist
na
inhibitor
develop
less
commonli
adamantan
depend
specif
mutat
viru
may
becom
resist
oseltamivir
remain
sensit
zanamivir
gubareva
et
al
moscona
b
moscona
first
step
develop
resist
often
mutat
ha
reduc
affin
sialic
acid
probabl
proper
balanc
hana
activ
requir
maxim
effici
spread
viru
among
respiratori
epitheli
cell
resist
virus
aris
cours
drug
treatment
usual
replic
lower
level
vitro
diminish
abil
caus
diseas
transmit
among
ferret
herloch
et
al
herloch
et
al
et
al
howev
revers
genet
method
use
introduc
certain
resist
mutat
virus
agent
retain
replic
capac
virul
yen
et
al
yen
et
al
b
yen
et
al
report
virus
resist
oseltamivir
rare
recent
two
studi
japan
found
almost
children
treat
drug
shed
resist
virus
kiso
et
al
subtherapeut
dose
may
play
role
similar
resist
seen
us
children
treat
dose
adjust
weight
moscona
oseltamivirresist
virus
also
recov
patient
southeast
asia
viru
recov
girl
treat
first
prophylact
therapeut
dose
oseltamivir
surviv
infect
show
resist
subpopul
virus
recov
two
patient
die
despit
earli
initi
oseltamivir
therapi
show
critic
mutat
na
activ
site
de
jong
et
al
b
le
et
al
virus
substitut
na
emerg
oseltamivir
treatment
retain
full
suscept
zanamivir
de
jong
et
al
gubareva
et
al
na
act
outsid
virusinfect
cell
inhibit
topic
administ
drug
aerosol
zanamivir
relenza
effect
reduc
impact
season
influenza
previous
healthi
adult
start
soon
onset
symptom
hayden
et
al
howev
drug
much
less
use
sever
ill
patient
unabl
inhal
whose
pulmonari
infect
inaccess
topic
therapi
medeiro
et
al
experi
report
use
zanamivir
prevent
treat
infect
activ
broad
rang
influenza
virus
drug
resist
rare
intraven
zanamivir
evalu
potenti
therapi
sever
influenza
far
efficaci
formal
test
uncompl
season
influenza
even
though
drug
plasma
halflif
shorter
oseltamivir
peramivir
twicedaili
infus
begin
h
intranas
viru
challeng
produc
signific
reduct
fever
upper
respiratori
tract
ill
viral
shed
volunt
calfe
et
al
kaiser
et
al
phase
trial
compar
pharmacokinet
interact
oral
oseltamivir
intraven
zanamivir
develop
wwwclinicaltrialsgov
effort
develop
second
gener
na
inhibitor
explor
activ
chemic
modifi
multimer
form
licens
compound
ether
deriv
zanamivir
show
increas
potenc
vitro
improv
oral
avail
greater
efficaci
mice
honda
et
al
masuda
et
al
dimer
form
zanamivir
particularli
promis
variant
act
manner
similar
antibodi
crosslink
influenza
virion
dimer
link
group
atom
length
potent
vitro
monomer
drug
macdonald
et
al
macdonald
et
al
vivo
halflif
construct
also
greatli
increas
administ
intranas
dimer
zanamivir
resid
time
rat
lung
exceed
week
singl
dose
prevent
death
mice
given
day
viru
challeng
synthesi
new
na
inhibitor
peramivir
structurebas
drug
design
report
babu
et
al
drug
inhibit
nine
na
subtyp
least
activ
oseltamivir
zanamivir
virus
vitro
govorkova
et
al
peramivir
offer
advantag
markedli
longer
halflif
bind
na
activ
site
permit
less
frequent
dose
bantia
et
al
gubareva
et
al
wherea
dissoci
halflif
zanamivir
oseltamivir
enzym
h
peramivir
exceed
day
singl
intramuscular
inject
h
postinfect
complet
protect
mice
challeng
lethal
dose
viru
bantia
et
al
although
oral
intranas
administr
protect
mice
ferret
chand
et
al
sweet
et
al
peramivir
low
oral
bioavail
human
thu
drug
well
toler
given
mouth
human
volunt
infect
influenza
b
viru
reduct
symptom
fail
achiev
statist
signific
bantia
et
al
subsequ
develop
therefor
focus
parenter
administr
phase
trial
intraven
peramivir
show
drug
halflif
plasma
well
toler
phase
ii
studi
way
evalu
singledos
intramuscular
peramivir
uncompl
season
influenza
wwwclinicaltrialsgov
second
random
control
trial
compar
efficaci
day
intraven
peramivir
current
approv
regimen
oral
oseltamivir
sever
influenza
wwwclinicaltrialsgov
treatment
combin
antivir
drug
differ
mechan
action
could
potenti
improv
outcom
sever
influenza
addit
possibl
synergist
suppress
viral
replic
might
also
reduc
requir
dose
drug
limit
toxic
emerg
drugresist
mutant
tsiodra
et
al
effort
model
approach
vitro
vivo
employ
combin
adamantan
na
inhibitor
thu
passag
virus
presenc
amantadin
oseltamivir
result
acquisit
drug
resist
procedur
repeat
presenc
drug
chang
detect
rimantadin
test
combin
zanamivir
oseltamivir
peramivir
three
combin
show
synergist
activ
isol
govorkova
et
al
mice
infect
viru
sensit
oseltamivir
amantadin
combin
therapi
produc
addit
benefit
oseltamivir
alon
gave
amantadin
alon
gave
surviv
combin
treatment
increas
rate
combin
therapi
also
significantli
decreas
viral
titer
lung
prevent
spread
brain
report
studi
human
treatment
sever
season
influenza
rimantadin
plu
zanamivir
suggest
virolog
benefit
compar
rimantadin
alon
ison
et
al
given
rang
new
antiinfluenza
therapi
develop
much
greater
varieti
combin
approach
may
soon
avail
test
exist
vast
reservoir
influenza
virus
wild
waterfowl
shorebird
abil
agent
jump
speci
barrier
mean
erad
alway
pose
threat
health
human
domest
anim
current
avail
antivir
therapi
develop
aim
reduc
impact
season
influenza
rather
treat
lifethreaten
diseas
emerg
virul
viru
forc
world
take
anoth
look
influenza
begin
approach
serious
deserv
new
better
antivir
therapi
need
deal
next
pandem
reduc
toll
ill
death
produc
everi
year
season
influenza
fortun
current
effort
show
promis
achiev
goal
